A new drug shown to help slow the progression of Alzheimer’s Disease, Leqembi, from drugmakers Eisai and Biogen, received accelerated approval by the FDA based on evidence that it clears amyloid plaque build-ups in the brain that are associated with Alzheimer’s Disease. Now, the Centers for Medicare and Medicaid Services said that it will expand coverage of the drug, broadening access for people with early forms of the disease and making it more accessible.

Join North Woods Village and Dr. Thomas Sweeney for this complimentary educational seminar to learn more about this new drug, how to access it, and other important considerations. Refreshments will be provided. Space is limited.